

Description

The PARP3 Chemiluminescent Assay Kit is designed to measure the activity of PARP3 (poly-(ADP-ribose) polymerase 3) for screening and profiling applications. The PARP3 assay kit comes in a convenient 384-well format, with enough recombinant purified PARP3 enzyme, reaction substrates, and PARP assay buffer for 400 enzyme reactions.




Figure 1. PARP3 Chemiluminescent Assay Kit schematic.

Histone proteins are coated on a 384-well plate. Next, a biotinylated NAD⁺ mix (termed PARP Substrate Mixture) is incubated with the PARP3 enzyme and an activated DNA template in an optimized assay buffer. The plate is then treated with streptavidin-HRP followed by addition of the ELISA ECL substrate to produce chemiluminescence that can be measured using a chemiluminescence reader. The chemiluminescence signal is proportional to PARP3 activity.

Background

PARP3, also known as poly-(ADP-ribose) polymerase 3 or NAD⁺ ADP-ribosyltransferase 3, is part of the PARP family. ADP ribosylation, which is the addition of an ADP-ribose to a protein, is a reversible post-translational modification of proteins mostly involved in the DNA Damage Response (DDR) pathway. Mono-ADP-ribosylation (termed MARYlation) is the addition of a unit of ADP-ribose. PARP3 is involved in programmed and stress-induced double strand break repair via classical NHEJ (non-homologous end-joining). In the absence of PARP3, DNA repair is less efficient, and cytotoxicity is potentiated when DNA damaging insults occur. It has been linked to cancer, with upregulation of PARP3 occurring in TGF β (transforming growth factor β)-induced cell EMT (epithelial to mesenchymal transition) in breast cancer. It also promotes cell stemness. The use of inhibitors towards PARP3 can refrain cells from EMT. In addition, the mTORC2 (mTOR complex 2) signaling pathway is impacted, contributing to synthetic lethality in cells deficient in a complementary DNA repair pathway, such as in BRCA1 (breast cancer type 1 susceptibility protein)- triple negative breast cancers (TNBC). PARP3 acts in synergy with PARP1 in the response to ionizing radiation, and the use of inhibitors for both PARP1 and PARP3 also provides an opportunity to reduce the concentration of both and decrease the radiation regimen.

Applications

Study enzyme kinetics and screen small molecule inhibitors for drug discovery and high throughput screening (HTS) applications.

Supplied Materials

Catalog #	Name	Amount	Storage
80503	PARP3, GST-Tag*	4.5 µg	-80°C
52029	5x Histone Mixture	2 x 1 ml	-80°C
78366	PARP Substrate Mixture 1	8 x 250 µl	-80°C
80602	10x PARP Assay Buffer	2 x 1 ml	-20°C
79743	Blocking Buffer 3	2 x 25 ml	+4°C
80605	Activated DNA	2 x 20 µl	-80°C
	0.5 M DTT	2 x 200 µl	-20°C
80611	Streptavidin-HRP	2 x 100 µl	+4°C
79670	ELISA ECL Substrate A (translucent bottle)	2 x 6 ml	Room Temp
	ELISA ECL Substrate B (brown bottle)	2 x 6 ml	Room Temp
78188	384-well white plate	1	Room Temp

*The concentration of the protein is lot-specific and will be indicated on the tube.

Materials Required but Not Supplied

- 1x PBS (Phosphate Buffer Saline) Buffer
- PBST Buffer (1x PBS, containing 0.05% Tween-20)
- Luminometer or microplate reader capable of reading chemiluminescence
- Adjustable micropipettor and sterile tips
- Rotating or rocker platform

Storage Conditions

This assay kit will perform optimally for up to **6 months** from date of receipt when the materials are stored as directed.

Safety

This product is for research purposes only and not for human or therapeutic use. This product should be considered hazardous and is harmful by inhalation, in contact with skin, eyes, clothing, and if swallowed. If contact occurs, wash thoroughly.

Contraindications

The PARP3 Chemiluminescent Assay Kit is compatible with up to 1% final DMSO concentration.

Assay Protocol

- All samples and controls should be performed in duplicate.
- The assay should include “Blank”, “Positive Control”, and “Test Inhibitor” conditions.
- We recommend maintaining the diluted protein on ice during use.
- For detailed information on protein handling please refer to Protein FAQs (bpsbioscience.com).
- We recommend using Olaparib (#78318 or #27003) as internal control. If not running a dose response curve for the control inhibitor, we recommend running the control inhibitor at 0.1X, 1X and 10X the IC₅₀ value shown in the validation data below.

Step 1: Coat 384-well module

1. Dilute 5x Histone Mixture 5-fold with PBS. This makes 1x Histone Mixture (25 µl/well).
2. Add 25 µl of 1x Histone Mixture to each well.
3. Incubate at 4°C overnight.
4. Wash the plate three times using 100 µl of PBST Buffer per well.
5. Tap the plate onto clean paper towel to remove the liquid.
6. Block the wells by adding 100 µl of Blocking Buffer 3 to every well.
7. Incubate at Room Temperature (RT) for at least 90 minutes.
8. Wash the plate three times with 100 µl of PBST Buffer per well.
9. Tap the plate onto clean paper towel to remove the liquid.

Step 2: Ribosylation reaction

1. Dilute Activated DNA 32-fold with PBS.
2. Dilute 0.5 M DTT 25-fold with distilled water. This makes a 20 mM DTT solution.
3. Prepare a Master Mix (12.5 µl/well): N wells x (1.25 µl of 10x PARP Assay Buffer + 5 µl of PARP Substrate Mixture 1 + 2.5 µl of diluted Activated DNA + 2.5 µl of distilled water + 1.25 µl of 20 mM DTT solution).
4. Add 12.5 µl of Master Mix to every well.
5. Prepare 1x PARP Assay Buffer by adding 1 volume of 10x PARP Assay Buffer and 1 volume of 20 mM DTT solution to 8 volumes of distilled water.
6. Prepare the Test Inhibitor (2.5 µl/well): for a titration prepare serial dilutions at concentrations 10-fold higher than the desired final concentrations. The final volume of the reaction is 25 µl.

6.1 If the Test Inhibitor is soluble in water, prepare a solution of the compound that is 10-fold higher than the final desired concentration in 1x PARP Assay Buffer.

For the positive and negative controls, use 1x PARP Assay Buffer (Diluent Solution).

OR

6.2 If the Test Inhibitor is dissolved in DMSO, prepare a solution of the compound in 100% DMSO that is 100-fold higher than the highest concentration of the serial dilution. Then dilute 10-fold with 1x PARP Assay Buffer (at this step the compound concentration is 10-fold higher than the desired final concentration). The concentration of DMSO in the dilution is now 10%.

Prepare serial dilutions of the Test Inhibitor at concentrations 10-fold higher than the desired final concentrations using 10% DMSO in 1x PARP Assay Buffer to keep the concentration of DMSO constant.

For positive and negative controls, prepare 10% DMSO in 1x PARP Assay Buffer (vol/vol) so that all wells contain the same amount of DMSO (Diluent Solution).

Note: The final concentration of DMSO should not exceed 1%.

7. Add 2.5 μ l of Test Inhibitor to each well labeled as "Test Inhibitor".
8. Add 2.5 μ l of Diluent Solution to the "Positive Control" and "Blank" wells.
9. Thaw **PARP3** enzyme on ice. Briefly spin the tube containing the enzyme to recover its full content.
10. Dilute PARP3 enzyme to **1.1 ng/ μ l** with 1x PARP Assay Buffer (10 μ l/ well).
11. Initiate the reaction by adding 10 μ l of diluted PARP3 enzyme to the wells designated "Positive Control" and "Test Inhibitor."
12. Add 10 μ l of 1x PARP Assay Buffer to the "Blank" wells.
13. Incubate at RT for 1 hour.

	Blank	Positive Control	Test Inhibitor
Master Mix	12.5 μ l	12.5 μ l	12.5 μ l
Test Inhibitor	-	-	2.5 μ l
Diluent Solution	2.5 μ l	2.5 μ l	-
1x PARP Assay Buffer	10 μ l	-	-
Diluted PARP3 (1.1 ng/ μ l)	-	10 μ l	10 μ l
Total	25 μl	25 μl	25 μl

14. Wash the plate three times with 100 μ l of PBST Buffer per well and tap the plate onto clean paper towel.

Step 3: Detection

1. Dilute Streptavidin-HRP 50-fold in Blocking Buffer 3 (25 μ l/well).
2. Add 25 μ l of diluted Streptavidin-HRP to every well.
3. Incubate for 30 minutes at RT.
4. Wash the plate three times with 100 μ l of PBST Buffer and tap the plate onto clean paper towel.
5. Just before use, mix 1 volume of ELISA ECL Substrate A and 1 volume of ELISA ECL Substrate B (50 μ l of mix/well).
6. Add 50 μ l of mix to every well.
7. Immediately read the plate in a luminometer or microtiter-plate reader capable of reading chemiluminescence.
8. The “Blank” value should be subtracted from all other values.

Reading Chemiluminescence

Chemiluminescence is the emission of light (luminescence) which results from a chemical reaction. The detection of chemiluminescence requires no wavelength selection because the method used is emission photometry and is not emission spectrophotometry.

To properly read chemiluminescence, make sure the plate reader is set for LUMINESCENCE mode. Typical integration time is 1 second, delay after plate movement is 100 msec. Do not use a filter when measuring light emission. Typical settings for the Synergy 2 BioTek plate reader are: use the “hole” position on the filter wheel; Optics position: Top; Read type: endpoint. Sensitivity may be adjusted based on the luminescence of a control assay without enzyme (typically we set this value as 100).

Example Results




Figure 2: Inhibition of PARP3 activity by Olaparib.

PARP3 was incubated with increasing concentrations of Olaparib (#78318 or #27003). Luminescence was measured using a Bio-Tek microplate reader.

Data shown is representative. For lot-specific information, please contact BPS Bioscience, Inc. at support@bpsbioscience.com.

References

Rodriguez-Vargas J., et al., 2019 *Cell Cycle* 18(12): 1295-1301.

Troubleshooting Guide

Visit bpsbioscience.com/assay-kits-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com

Related Products

Products	Catalog #	Size
PARP3 Homogeneous Assay Kit	78491	384 reactions
PARP1 Chemiluminescent Assay Kit	80551	96 reactions
PARP2 Chemiluminescent Assay Kit	80552	96 reactions/384 reactions
TNKS1 (PARP5A) Chemiluminescent Assay Kit	78405	96 reactions/384 reactions
TNKS2 (PARP5B) Chemiluminescent Assay Kit	78406	96 reactions

Version 031524